Patient and graft characteristics
| Characteristics . | Haploidentical, N = 231 . | Identical sibling, N = 219 . |
|---|---|---|
| Age, y, median (range) | 28 (15-57) | 40 (17-60) |
| Gender, no. (%) | ||
| Male | 144 (62) | 122 (56) |
| Female | 87 (38) | 97 (44) |
| French-American-British subtype, no. (%) | ||
| M0 | 5 (2) | 6 (3) |
| M1 | 11 (5) | 23 (10) |
| M2 | 105 (46) | 85 (39) |
| M4 | 25 (11) | 30 (14) |
| M5 | 68 (29) | 54 (25) |
| M6 | 11 (5) | 12 (5) |
| M7 | 1 (0.4) | 1 (0.5) |
| Undetermined | 5 (2) | 8 (4) |
| WBC count at diagnosis | 16.9 (0.3-368) | 1.8 (0.5-418) |
| <50 000/mm3, no. (%) | 159 (69) | 164 (75) |
| >50 000/mm3, no. (%) | 72 (31) | 55 (25) |
| Duration from diagnosis to transplant, mo | ||
| Median (range) | 6.0 (2.0-12) | 5.0 (2.0-12) |
| Cytogenetic risk group,*no. (%) | ||
| Intermediate, normal | 99 (43) | 110 (50) |
| Intermediate, abnormal | 84 (36) | 77 (35) |
| High | 48 (21) | 32 (15) |
| Autosome monosomal karyotype among abnormals | ||
| No | 119 (90) | 105 (96) |
| Yes | 13 (10) | 4 (4) |
| Courses required achieving remission, no. (%) | ||
| 1 | 155 (67) | 156 (71) |
| 2 | 60 (26) | 50 (23) |
| 3-4 | 16 (7) | 13 (6) |
| Donor-patient sex matched, no. (%) | ||
| Male to male | 90 (39) | 65 (30) |
| Male to female | 55 (24) | 61 (28) |
| Female to male | 51 (22) | 57 (26) |
| Female to female | 35 (15) | 36 (16) |
| Donor-patient relation, no. (%) | ||
| Father donor | 76 (33) | |
| Mother donor | 39 (17) | |
| Sibling donor | 92 (40) | 219 (100) |
| Children donor | 24 (10) | |
| Graft type, no. (%) | ||
| BM + PB cell | 231 (100) | 124 (57) |
| BM | 14 (6) | |
| PB cell | 81 (37) | |
| Median nucleated cells, ×108 cells per kg (range) | 7.6 (4.2-15.8) | 7.2 (4.0-12.4) |
| Median CD34+ cells, ×106/kg (range) | 2.5 (0.4-17.0) | 2.2 (0.3-8.3) |
| Follow-up time in survivors from complete remission, mo | ||
| No. of evaluable patients | 188 (81%) | 184 (84%) |
| Median (range) | 36 (16-63) | 37 (14-66) |
| Characteristics . | Haploidentical, N = 231 . | Identical sibling, N = 219 . |
|---|---|---|
| Age, y, median (range) | 28 (15-57) | 40 (17-60) |
| Gender, no. (%) | ||
| Male | 144 (62) | 122 (56) |
| Female | 87 (38) | 97 (44) |
| French-American-British subtype, no. (%) | ||
| M0 | 5 (2) | 6 (3) |
| M1 | 11 (5) | 23 (10) |
| M2 | 105 (46) | 85 (39) |
| M4 | 25 (11) | 30 (14) |
| M5 | 68 (29) | 54 (25) |
| M6 | 11 (5) | 12 (5) |
| M7 | 1 (0.4) | 1 (0.5) |
| Undetermined | 5 (2) | 8 (4) |
| WBC count at diagnosis | 16.9 (0.3-368) | 1.8 (0.5-418) |
| <50 000/mm3, no. (%) | 159 (69) | 164 (75) |
| >50 000/mm3, no. (%) | 72 (31) | 55 (25) |
| Duration from diagnosis to transplant, mo | ||
| Median (range) | 6.0 (2.0-12) | 5.0 (2.0-12) |
| Cytogenetic risk group,*no. (%) | ||
| Intermediate, normal | 99 (43) | 110 (50) |
| Intermediate, abnormal | 84 (36) | 77 (35) |
| High | 48 (21) | 32 (15) |
| Autosome monosomal karyotype among abnormals | ||
| No | 119 (90) | 105 (96) |
| Yes | 13 (10) | 4 (4) |
| Courses required achieving remission, no. (%) | ||
| 1 | 155 (67) | 156 (71) |
| 2 | 60 (26) | 50 (23) |
| 3-4 | 16 (7) | 13 (6) |
| Donor-patient sex matched, no. (%) | ||
| Male to male | 90 (39) | 65 (30) |
| Male to female | 55 (24) | 61 (28) |
| Female to male | 51 (22) | 57 (26) |
| Female to female | 35 (15) | 36 (16) |
| Donor-patient relation, no. (%) | ||
| Father donor | 76 (33) | |
| Mother donor | 39 (17) | |
| Sibling donor | 92 (40) | 219 (100) |
| Children donor | 24 (10) | |
| Graft type, no. (%) | ||
| BM + PB cell | 231 (100) | 124 (57) |
| BM | 14 (6) | |
| PB cell | 81 (37) | |
| Median nucleated cells, ×108 cells per kg (range) | 7.6 (4.2-15.8) | 7.2 (4.0-12.4) |
| Median CD34+ cells, ×106/kg (range) | 2.5 (0.4-17.0) | 2.2 (0.3-8.3) |
| Follow-up time in survivors from complete remission, mo | ||
| No. of evaluable patients | 188 (81%) | 184 (84%) |
| Median (range) | 36 (16-63) | 37 (14-66) |
Patient age and duration from diagnosis to transplant differed significantly between the 2 groups (P < .001). There were no other significant between-group differences.
BM, bone marrow; PB, peripheral blood; WBC, white blood cell.
Cytogenetic studies were carried out using standard techniques. Molecular screening for fusion genes was offered to all patients. Patients were classified as low, intermediate, or high risk on the basis of National Comprehensive Cancer Network cytogenetic abnormalities. Cytogenetic abnormalities t(8;21)(q22;q22), t(15;17)(q22;q21), and inv(16) or t(16;16)(p13;q22) were considered low risk. Complex cytogenetic abnormalities (defined as at least 3 unrelated cytogenetic clones) and −5/5q-, −7/7q-, abn(3q), t(6;9)(q23;q34), abn(11q23)-non t(9;11), and t(9;22)(q34;q11) were considered high risk. Patients without favorable (low risk) or adverse (high risk) abnormalities or without karyotype information were classified as intermediate risk.12 Patients were not reclassified according to the recently published Center for International Blood and Marrow Transplant criteria because only 10 patients fit in the adverse group.14 Information on FLT3 internal tandem duplication (ITD) was only available in 187 patients (positive in 40 and negative in 147). Information on NPM1 was available in 222 patients (normal karyotype with NPM1 mutation and FLT3-ITD in 11 patients, abnormal karyotype with NPM1 mutation in 11 patients, normal karyotype with NPM1 wild type in 110 patients, and abnormal karyotype with NPM1 wild type in 90 patients).